• Explore /
  • Journal
  • / Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed

Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed

Authors

null

Claudia Rossig

Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany

Claudia Rossig, Andrew D. Pearson, Gilles Vassal, Nicole Scobie, Nick Bird, Patricia Blanc, H. Josef Vormoor, Friso G. Calkoen, Franco Locatelli, Francesca del Bufalo, Susana Rives, Elad Jacoby, Adriana Balduzzi, Jean-Pierre Bourquin, André Baruchel

Preview

We call for a concerted action to enable academia to develop novel cell therapies for the benefit of children.

View Full Journal Article

Journal Details

DOI

10.1200/JCO.23.01314

Published Date

November 27, 2023

Similar Journals

First Author: Jing Pan

Publish Date: Jul 1, 2021

Journal

Journal of Clinical Oncology

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

First Author: Nirali N. Shah

Publish Date: Mar 25, 2021

First Author: Nirali N. Shah

Publish Date: Apr 1, 2020

Journal

Journal of Clinical Oncology

CAR T-Cells for Cure in Pediatric B-ALL

First Author: Rebecca A. Gardner

Publish Date: Jan 12, 2023